UCB (WBO:UCB) Total Liabilities: €7,291 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:UCB UCB SA WBO:UCB
80 GF Score
Price €231.80
GF Value €213.75
Valuation Fairly Valued
View Full Analysis

What is UCB Total Liabilities?

UCB WBO:UCB -1.74% 80 Total Liabilities is €7,291 Mil as of Dec. 2025. GuruFocus rates WBO:UCB with a GF Score™ of 80/100 and a GF Value™ of €213.75 (Fairly Valued).

UCB's Total Liabilities for the quarter that ended in Dec. 2025 was €7,291 Mil.

UCB's quarterly Total Liabilities increased from Dec. 2024 (€7,318.00 Mil) to Jun. 2025 (€7,503.00 Mil) but then declined from Jun. 2025 (€7,503.00 Mil) to Dec. 2025 (€7,291.00 Mil).

UCB's annual Total Liabilities increased from Dec. 2023 (€6,564.00 Mil) to Dec. 2024 (€7,318.00 Mil) but then declined from Dec. 2024 (€7,318.00 Mil) to Dec. 2025 (€7,291.00 Mil).

UCB Total Liabilities Historical Data

* Premium members only.

The historical data trend for UCB's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Total Liabilities Chart

UCB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,824.00 6,804.00 6,564.00 7,318.00 7,291.00

UCB Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,564.00 6,676.00 7,318.00 7,503.00 7,291.00
WBO:UCB
80GF Score
UCB SA WBO:UCB
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

UCB's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4401+(2183+370
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+159+178)
=7,291

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=18158-10867
=7,291

UCB's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4401+(2183+370
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+159+178)
=7,291

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=18158-10867
=7,291

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €7,291 Mil mean?
UCB (WBO:UCB) has a Total Liabilities of €7,291 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for UCB and its competitors.
Is UCB's Total Liabilities too high?
UCB's current Total Liabilities is €7,291 Mil. Overall, UCB has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does UCB's Total Liabilities compare to VRTX and REGN?
UCB's Total Liabilities of €7,291 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for UCB and its competitors. UCB's current Total Liabilities is €7,291 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (WBO:UCB) is currently considered Fairly Valued. The stock's GF Value™ is €213.75, compared to a current price of €231.80 — trading 8.4% above its estimated fair value. The current Total Liabilities is €7,291 Mil. UCB's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For UCB (WBO:UCB), the current Total Liabilities is €7,291 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (WBO:UCB) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be overvalued. The current stock price of €231.80 is trading 8.4% above its estimated GF Value™ of €213.75. GuruFocus considers UCB to be Fairly Valued.

Key valuation signals for WBO:UCB:

  • Total Liabilities: €7,291 Mil
  • GF Value™: €213.75 vs. price of €231.80 (8.4% above fair value)
  • GF Score™: 80/100

No single metric tells the full story. See the WBO:UCB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
80GF Score

Get the complete analysis for WBO:UCB

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€231.80
Price
€213.75
GF Value